Zhang Hui, Liu Ruiqi, Chen Yanrong, Ma Ruicong, Xue Qiang, Sahu Arvind, Yan Xiaodi, Gu Hongmei
Department of Radiation Oncology, Affiliated Hospital of Nantong University, Nantong, China.
Department of Clinical Medicine, Medical College, Nantong University, Nantong, China.
J Gastrointest Oncol. 2024 Feb 29;15(1):63-85. doi: 10.21037/jgo-23-984. Epub 2024 Feb 28.
The discovery of biomarkers has facilitated the treatment of cancer. At present, the relationship between activin A receptor type-1 () and gastric cancer is gradually discovered. The aim of this study was to explore the expression of in gastric cancer and its clinical significance, to study the relationship between and tumor microenvironment (TME) for the prognosis of gastric cancer, and to further identify new targets for immunotherapy in gastric cancer.
was first selected as a study gene according to several cancer and gastric cancer public datasets. Its pancancer expression was explored using the UCSC Xena database. The expression level, prognosis, and clinicopathological features of in gastric cancer were analyzed using The Cancer Genome Atlas (TCGA) database. Immunohistochemistry (IHC)-based experiments were conducted to study the expression of at the protein level. The IHC data were analyzed for correlations between expression and various clinicopathological factors and prognosis. The correlation of this gene with the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway, immune infiltration, immune checkpoints, drug therapy, tumor mutation burden (TMB), microsatellite instability (MSI), and mismatch repair (MMR) system was analyzed using R software.
TCGA data showed that the expression of was higher in gastric cancer tissues than in paracancerous tissues. Moreover, the IHC experiments indicated that was upregulated in gastric cancer tissues at the protein level. Both univariate Cox and multivariate Cox results showed that the increase of was closely associated with tumor stage, size, lymph node metastasis, and age. High expression was linked to a poor prognosis of gastric cancer. The results also revealed that was closely related to suppressive immune cells and pathways. Analyses of immune checkpoints, antitumor drug, TMB, and immune microenvironment indicated that had an antitumor immune effect, promoting gastric cancer development and leading to poor immunotherapy.
High expression can be used as an independent prognostic factor to predict the prognostic survival of patients with gastric cancer. expression in gastric cancer tissues was significantly correlated with immune infiltration and may thus serve as a potential therapeutic target for gastric cancer immunotherapy.
生物标志物的发现推动了癌症的治疗。目前,1型激活素A受体( )与胃癌之间的关系正逐渐被揭示。本研究旨在探讨 在胃癌中的表达及其临床意义,研究 与肿瘤微环境(TME)对胃癌预后的关系,并进一步确定胃癌免疫治疗的新靶点。
根据多个癌症和胃癌公共数据集,首先选择 作为研究基因。使用UCSC Xena数据库探索其泛癌表达。利用癌症基因组图谱(TCGA)数据库分析 在胃癌中的表达水平、预后及临床病理特征。进行基于免疫组织化学(IHC)的实验以研究 在蛋白水平的表达。分析IHC数据中 表达与各种临床病理因素及预后之间的相关性。使用R软件分析该基因与京都基因与基因组百科全书(KEGG)通路、免疫浸润、免疫检查点、药物治疗、肿瘤突变负荷(TMB)、微卫星不稳定性(MSI)和错配修复(MMR)系统的相关性。
TCGA数据显示, 在胃癌组织中的表达高于癌旁组织。此外,IHC实验表明, 在胃癌组织中的蛋白水平上调。单因素Cox和多因素Cox结果均显示, 的升高与肿瘤分期、大小、淋巴结转移及年龄密切相关。 高表达与胃癌预后不良相关。结果还显示, 与抑制性免疫细胞及通路密切相关。对免疫检查点、抗肿瘤药物、TMB和免疫微环境的分析表明, 具有抗肿瘤免疫作用,促进胃癌发展并导致免疫治疗效果不佳。
高表达可作为预测胃癌患者预后生存的独立预后因素。 在胃癌组织中的表达与免疫浸润显著相关,因此可能成为胃癌免疫治疗的潜在靶点。